{"id":818729,"date":"2026-08-19T12:00:22","date_gmt":"2026-08-19T12:00:22","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/818729\/"},"modified":"2026-08-19T12:00:22","modified_gmt":"2026-08-19T12:00:22","slug":"eli-lilly-stock-jumps-2-6-as-investors-flee-expensive-tech","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/818729\/","title":{"rendered":"Eli Lilly Stock Jumps 2.6% as Investors Flee Expensive Tech"},"content":{"rendered":"\n

This article first appeared on GuruFocus<\/a>. <\/p>\n

Eli Lilly (NYSE:LLY<\/a>), the pharmaceutical powerhouse behind Mounjaro and Zepbound, jumped<\/a> approximately 2.6% to $1,213.76 Tuesday morning as investors searched for earnings growth outside pressured technology stocks. With its market capitalization climbing above $1.08 trillion, Lilly is proving that healthcare can still command investor attention when growth remains tangible. <\/p>\n

The reason is simple: Lilly’s obesity franchise has become one of the most powerful growth engines in global healthcare. Second-quarter revenue<\/a> surged 48% to $23 billion, while adjusted earnings climbed 33% to $8.38 per share. Mounjaro delivered $9.9 billion in sales, up 91% year over year, while Zepbound added $4.9 billion as demand for weight-loss treatments continued accelerating. Together, the two medicines generated roughly 64% of quarterly revenue, showing just how important the obesity opportunity has become for Lilly’s future. <\/p>\n

\"Eli<\/a> Eli Lilly Stock Jumps 2.6% as Investors Flee Expensive Tech \u00b7 us.finance.gurufocus <\/p>\n

The GuruFocus valuation picture adds another layer to the story. The GF Value chart shows Lilly trading around $1,219 per share versus an estimated intrinsic value of approximately $1,510, suggesting the stock sits about 19.4% below its calculated fair value. The market is paying a premium for Lilly’s growth, but investors appear to be betting that today’s blockbuster drugs can become tomorrow’s healthcare empire. The challenge is concentration: two medicines now carry a huge portion of the company’s growth story, leaving Lilly needing continued prescription momentum, pricing power, and successful pipeline execution to justify its trillion-dollar valuation. <\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the pharmaceutical powerhouse behind Mounjaro and Zepbound, jumped approximately…\n","protected":false},"author":2,"featured_media":68209,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[59],"tags":[11971,48123,18538,97,252,253],"class_list":["post-818729","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-care","tag-earnings-growth","tag-eli-lilly","tag-gurufocus","tag-health","tag-health-care","tag-healthcare"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/818729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=818729"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/818729\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/68209"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=818729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=818729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=818729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}